Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Gilead Sciences, Inc.    GILD   US3755581036

GILEAD SCIENCES, INC. (GILD)

290
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

05/11/2012 | 03:06pm US/Eastern
   By Jennifer Corbett Dooren 
   Of  
 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

Latest news on GILEAD SCIENCES, INC.
4d ago GILEAD SCIENCES : Health Canada issues notice of compliance for Gilead's Harvoni..
4d ago GILEAD SCIENCES : Health Canada Issues Notice of Compliance for Gilead’s H..
4d ago Top investors, strategists take pummeling in Wall St sell-off
4d ago GILEAD SCIENCES : FDA OKs Gilead's Harvoni (Ledipasvir/Sofosbuvir)
5d ago GILEAD SCIENCES : Patent Issued for Methods and Intermediates for Preparing Phar..
6d ago S&P 500, Nasdaq break three-day slide but Dow dips
6d ago S&P 500 MOVERS : Gild, cci
6d ago NASDAQ 100 MOVERS : Gild, symc
6d ago J&J beats forecasts, helped by hepatitis drug
6d ago J&J beats forecasts, helped by hepatitis drug
Advertisement
Chart
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF